Influence of statin use on prognosis of patients with renal cell cancer: a meta-analysis

Frontiers in Oncology

Oncology

Yongmei Pan¹  Yan He²  Aixue Liu²  Yan Zhu²  Wenli Liang² 

[1] Department of Medical Imaging, the First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan, China;Oncology Department, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, China;

关键词: statin;    renal cell cancer;    survival;    prognosis;    meta-analysis;   

DOI  :  10.3389/fonc.2023.1132177

 received in 2022-12-27, accepted in 2023-03-14,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundStatin may confer anticancer efficacy, while the studies evaluating the influence of statin on survival of patients with renal cell cancer (RCC) yielded inconsistent results. A systematic review and meta-analysis was performed to investigate the association between statin use and survival of patients with RCC.Materials and MethodsCohort studies were identified by search of PubMed, Embase, and Web of Science databases according to the objective of the meta-analysis. A random-effect model incorporating the possible between-study heterogeneity was used for meta-analysis. Subgroup analyses according to study characteristics were also performed.ResultsSeventeen cohort studies involving 42528 patients with RCC were available for the meta-analysis. Results showed that statin use was associated with a better overall survival (OS, hazard ratio [HR]: 0.73, 95% confidence interval [CI]: 0.65 to 0.84, p < 0.001; I2 = 40%), progression progression-free survival (PFS, HR: 0.82, 95% CI: 0.68 to 0.98, p = 0.03; I2 = 52%), and cancer-specific survival (CSS, HR: 0.76, 95% CI: 0.59 to 0.99, p = 0.04; I2 = 38%). Besides, for the outcome of OS and PFS, subgroup analyses showed similar results in patients with surgical and non-surgical anticancer treatments, and in patients with stage I-III and stage IV RCC (p values for subgroup difference all > 0.05).ConclusionsStatin use may be associated with improved survival outcomes in patients with RCC. Although prospective clinical studies should be considered to validate these results, these findings suggest that statins may be potential adjuvant therapy for patients with RCC.

【 授权许可】

Unknown   
Copyright © 2023 Liang, Pan, Liu, He and Zhu